UK Markets closed
  • FTSE 100

    6,367.58
    +4.65 (+0.07%)
     
  • FTSE 250

    19,462.71
    +66.37 (+0.34%)
     
  • AIM

    1,039.01
    +0.98 (+0.09%)
     
  • GBP/EUR

    1.1120
    -0.0091 (-0.81%)
     
  • GBP/USD

    1.3313
    -0.0044 (-0.3288%)
     
  • BTC-GBP

    12,920.55
    +180.05 (+1.41%)
     
  • CMC Crypto 200

    333.27
    -4.23 (-1.25%)
     
  • S&P 500

    3,638.35
    +8.70 (+0.24%)
     
  • DOW

    29,910.37
    +37.90 (+0.13%)
     
  • CRUDE OIL

    45.53
    -0.18 (-0.39%)
     
  • GOLD FUTURES

    1,788.10
    -23.10 (-1.28%)
     
  • NIKKEI 225

    26,644.71
    +107.40 (+0.40%)
     
  • HANG SENG

    26,894.68
    +75.23 (+0.28%)
     
  • DAX

    13,335.68
    +49.11 (+0.37%)
     
  • CAC 40

    5,598.18
    +31.39 (+0.56%)
     

EVOTEC SE REPORTS RESULTS FOR THE FIRST NINE MONTHS 2020 AND PROVIDES CORPORATE UPDATE

·7-min read

DGAP-News: Evotec SE / Key word(s): 9 Month figures
12.11.2020 / 07:02
The issuer is solely responsible for the content of this announcement.

 


HIGHLIGHTS

CONTINUED STRONG PERFORMANCE IN BASE BUSINESS; ROBUST REVENUE GROWTH AND IMPROVING EBITDA IN Q3


EVT EXECUTE & EVT INNOVATE - MULTIMODALITY AND INTEGRATED PLATFORM SET FOR GROWTH IN DATA DRIVEN PRECISION MEDICINE

CORPORATE

GUIDANCE FOR FULL-YEAR 2020 CONFIRMED

Key figures of consolidated income statement & segment information>
Evotec SE & subsidiaries - First nine months of 2020

1) Revenues in the segments consist of revenues from contracts with customers without revenues from recharges as those are not of importance for management when assessing the economic situation of the segments.
2) Of which unpartnered R&D expenses of € 33.4 m in 9M 2020 (9M 2019: € 25.7 m)
3) Before contingent considerations, income from bargain purchase and excluding impairments on goodwill, other 
intangible and tangible assets as well as the total non-operating result; adjusted for negative exchange rate effects of  € 0.5 m, EBITDA amounts to € 77.4 m
4) Not allocated to segments: Revenues from recharges according to IFRS 15


More detailed information and financial tables are available in our nine months quarterly statement published on the Evotec website under the following link:
https://www.evotec.com/en/invest/financial-publications.


Webcast/Conference Call

The Company is going to hold a conference call to discuss the results of the first nine months 2020 as well as to provide an update on its performance in the reporting period. The conference call will be held in English.


Conference call details
Date: Thursday, 12 November 2020
Time: 02.00 pm CET (08.00 am EST, 01.00 pm GMT)

From Germany: +49 69 20 17 44 220
From France: +33 170 709 502
From Italy: +39 023 600 6663
From UK: +44 20 3009 2470
From USA: +1 877 423 0830
Access Code: 69782681#

A simultaneous slide presentation for participants dialling in via phone is available at https://www.webcast-eqs.com/evotec20201112/no-audio.


Webcast details
To join the audio webcast and to access the presentation slides you will find a link on our homepage www.evotec.com shortly before the event.

A replay of the conference call will be available for seven days and can be accessed from Germany by dialling +49 69 201744221, from UK by dialling +44 20 3364 5150 and from USA by dialling +1 (844) 307-9362.

The access code is 315597280#. The on-demand version of the webcast will be available on our website: https://www.evotec.com/financial-reports.


ABOUT EVOTEC SE
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,400 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to
www.evotec.com and follow us on Twitter @Evotec.


FORWARD-LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.


IR Contact Evotec SE:
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com

Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com

 


12.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



In T€


EVT
Execute


EVT
Innovate


Intersegment Eliminations



Transition4)

Evotec Group
9M 2020

Evotec Group
9M 2019

External revenues1)

269,860

74,692

-

15,862

360,414

321,362

Intersegment revenues

82,802

-

(82,802)

-

-

-

Costs of revenues

(262,154)

(68,668)

75,459

(15,862)

(271.225)

(222,553)

Gross profit

90,508

6,024

(7,343)

-

89,189

98,809

Gross margin in %

25.7

8.1

-

-

24.7

30.7

 

 

 

 

 

 

 

R&D expenses2)

(3,589)

(49,831)

7,343

-

(46,077)

(41,285)

SG&A expenses

(47,402)

(10,730)

-

-

(58,132)

(46,230)

Impairments of intangible assets and goodwill

-

-

-

-

-

(11,919)

Other operating
income (expenses), net

13,661

36,645

-

-

50,306

47,050

Operating result

53,178

(17,892)

-

-

35,286

46,425

 

 

 

 

 

 

 

Adjusted EBITDA3)

92,303

(15,361)

-

-

76,942

93,216



In T€


EVT
Execute


EVT
Innovate


Intersegment Eliminations



Transition4)

Evotec Group
9M 2020

Evotec Group
9M 2019

External revenues1)

269,860

74,692

-

15,862

360,414

321,362

Intersegment revenues

82,802

-

(82,802)

-

-

-

Costs of revenues

(262,154)

(68,668)

75,459

(15,862)

(271.225)

(222,553)

Gross profit

90,508

6,024

(7,343)

-

89,189

98,809

Gross margin in %

25.7

8.1

-

-

24.7

30.7

 

 

 

 

 

 

 

R&D expenses2)

(3,589)

(49,831)

7,343

-

(46,077)

(41,285)

SG&A expenses

(47,402)

(10,730)

-

-

(58,132)

(46,230)

Impairments of intangible assets and goodwill

-

-

-

-

-

(11,919)

Other operating
income (expenses), net

13,661

36,645

-

-

50,306

47,050

Operating result

53,178

(17,892)

-

-

35,286

46,425

 

 

 

 

 

 

 

Adjusted EBITDA3)

92,303

(15,361)

-

-

76,942

93,216

Language:

English

Company:

Evotec SE

Manfred Eigen Campus / Essener Bogen 7

22419 Hamburg

Germany

Phone:

+49 (0)40 560 81-0

Fax:

+49 (0)40 560 81-222

E-mail:

info@evotec.com

Internet:

www.evotec.com

ISIN:

DE0005664809

WKN:

566480

Indices:

MDAX, TecDAX

Listed:

Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

EQS News ID:

1147496


 

End of News

DGAP News Service

show this
show this